Advanced search
Publication Cover
Journal of Psychoactive Drugs Volume 51, 2019 - Issue 2: 50th Anniversary: Psychedelic Research Today
Submit an article Journal homepage
3,733
Views
50
CrossRef citations to date
0
Altmetric
Review Article

Psychedelic-Assisted Group Therapy: A Systematic Review

Alexander TropeDepartment of Psychiatry, Weill Institute for Neurosciences, UCSF, San Francisco, CA, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-1034-9110View further author information
ORCID Icon,
Brian T. AndersonDepartment of Psychiatry, Weill Institute for Neurosciences, UCSF, San Francisco, CA, USA;Mental Health Service, San Francisco VA Medical Center, San Francisco, CA, USAORCID Iconhttp://orcid.org/0000-0001-5023-660XView further author information
ORCID Icon,
Andrew R. HookerOsher Center for Integrative Medicine, UCSF, San Francisco, CA, USAORCID Iconhttp://orcid.org/0000-0002-7027-5144View further author information
ORCID Icon,
Giancarlo GlickSchool of Medicine, Brown University, Providence, RI, USAORCID Iconhttp://orcid.org/0000-0003-1089-7715View further author information
ORCID Icon,
Christopher StaufferDepartment of Psychiatry, Weill Institute for Neurosciences, UCSF, San Francisco, CA, USA;Mental Health Service, San Francisco VA Medical Center, San Francisco, CA, USAORCID Iconhttp://orcid.org/0000-0002-0888-095XView further author information
ORCID Icon &
Joshua D. WoolleyDepartment of Psychiatry, Weill Institute for Neurosciences, UCSF, San Francisco, CA, USA;Mental Health Service, San Francisco VA Medical Center, San Francisco, CA, USAORCID Iconhttp://orcid.org/0000-0001-6753-2093View further author information
ORCID Icon
Pages 174-188 | Received 19 Nov 2018, Accepted 20 Feb 2019, Published online: 05 Apr 2019

Citations (50)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Isaac Burt. (2024) Scientifically Integrating Psychedelics with Counseling: Education, Guidance, and Implications for Mental Health Practitioners. Journal of Creativity in Mental Health 19:2, pages 275-287.
Read now
Raul Escamilla, María Eva González-Trujano, Jesús M. González Mariscal, Jesús Martín Torres-Valencia, Héctor Guzmán-González, José Luis Vega & Anja Loizaga-Velder. (2023) A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder. Journal of Psychoactive Drugs 55:5, pages 570-580.
Read now
Vivian W. L. Tsang, Dragos C. Ragazan, Pamela Kryskow, Zach Walsh & Shannon Dames. (2023) A Pilot Study Comparing a Community of Practice Program with and without Concurrent Ketamine-Assisted Therapy. Journal of Psychoactive Drugs 0:0, pages 1-10.
Read now

Articles from other publishers (47)

Nikita P. Ilyin, Arslan D. Nabiullin, Anna D. Kozlova, Olga V. Kupriyanova, Vadim A. Shevyrin, Tatyana Gloriozova, Dmitry Filimonov, Alexey Lagunin, David S. Galstyan, Tatiana O. Kolesnikova, Mikael S. Mor, Evgeniya V. Efimova, Vladimir Poroikov, Konstantin B. Yenkoyan, Murilo S. de Abreu, Konstantin A. Demin & Allan V. Kalueff. (2024) Chronic Behavioral and Neurochemical Effects of Four Novel N -Benzyl-2-phenylethylamine Derivatives Recently Identified as “Psychoactive” in Adult Zebrafish Screens . ACS Chemical Neuroscience 15:10, pages 2006-2017.
Crossref
Mirko Casu, Chiara Farrauto, Giorgia Farruggio, Salvatore Bellissima, Sebastiano Battiato & Pasquale Caponnetto. (2024) Exploring the Therapeutic Potential of Virtual Reality: A Review on the Simulation of Psychedelic Effects for Treating Psychological Disorders. Psychology International 6:2, pages 603-617.
Crossref
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, Josimar Hernandez Antonio, Philip A. Bonanno, Carolyn MacLeod, Charlotte Pierce, Hunter Carney, Morgan T. Morrison, Charles Saylor, George Danias, Lauren Lepow & Rachel Yehuda. (2024) The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. Current Neuropharmacology 22:4, pages 636-735.
Crossref
Yvan Beaussant, Elise Tarbi, Kabir Nigam, Skye Miner, Zachary Sager, Justin J. Sanders, Michael Ljuslin, Benjamin Guérin, Paul Thambi, James A. Tulsky & Manish Agrawal. (2023) Acceptability of psilocybin‐assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis. Cancer 130:7, pages 1147-1157.
Crossref
Robert Swoap. (2023) Psychedelic Healing: A Historical, Empirical, and Personal Account. American Journal of Health Promotion 38:1, pages 143-148.
Crossref
Jay E. Maddock & Sara S. Johnson. (2023) Spending Time in Nature: The Overlooked Health Behavior. American Journal of Health Promotion 38:1, pages 124-148.
Crossref
Elliot Marseille, Christopher S. Stauffer, Manish Agrawal, Paul Thambi, Kimberly Roddy, Michael Mithoefer, Stefano M. Bertozzi & James G. Kahn. (2023) Group psychedelic therapy: empirical estimates of cost-savings and improved access. Frontiers in Psychiatry 14.
Crossref
Priyanshu Raj, Shyambabu Rauniyar & Bhagyesh Sapkale. (2023) Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential. Cureus.
Crossref
Bruno Pires, Luana M. Rosendo, Ana Teresa Brinca, Ana Y. Simão, Mário Barroso, Tiago Rosado & Eugenia Gallardo. (2023) The Therapeutic Potential of Amphetamine-like Psychostimulants. Life 13:11, pages 2180.
Crossref
Jakub Greń, Filip Tylš, Michał Lasocik & Csaba Kiraly. (2023) Back from the rabbit hole. Theoretical considerations and practical guidelines on psychedelic integration for mental health specialists. Frontiers in Psychology 14.
Crossref
Benjamin R. Lewis, Eric L. Garland, Kevin Byrne, Tyler Durns, John Hendrick, Anna Beck & Paul Thielking. (2023) HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer. Journal of Pain and Symptom Management 66:3, pages 258-269.
Crossref
Richard Chambers, Devon Stoliker & Otto Simonsson. (2023) Psychedelic-Assisted Psychotherapy and Mindfulness-Based Cognitive Therapy: Potential Synergies. Mindfulness 14:9, pages 2111-2123.
Crossref
Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, Austin Mallard, Daniel E. Roberts, David Erritzoe, Stephen Ross & Robin L. Carhart-Harris. (2023) Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences. Scientific Reports 13:1.
Crossref
Patric Plesa & Rotem Petranker. (2023) Psychedelics and neonihilism: connectedness in a meaningless world. Frontiers in Psychology 14.
Crossref
Gregory S. BarberCharles C. Dike. (2023) Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry. Psychiatric Services 74:8, pages 838-846.
Crossref
Polina Ponomarenko, Federico Seragnoli, Abigail Calder, Peter Oehen & Gregor Hasler. (2023) Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors. Journal of Psychopharmacology 37:7, pages 660-678.
Crossref
Xuepeng Jing, Nicholas R. Hoeh & David B. Menkes. (2023) Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022. Palliative and Supportive Care, pages 1-8.
Crossref
Fahad S. Alshehri. (2023) A Review of the Characteristics of Clinical Trials and Potential Medications for Alcohol Dependence: Data Analysis from ClinicalTrials.gov. Medicina 59:6, pages 1101.
Crossref
Noah D. Gold, Samantha K. PodrebaracLindsay A. WhiteChristina MariniNaomi M. SimonMary S. MittelmanStephen RossMichael P. BogenschutzPetros D. Petridis. (2023) Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress. Psychedelic Medicine 1:2, pages 87-97.
Crossref
Alexander De Foe. (2023) Considerations in the Application of Psychedelic-Augmented Psychotherapy: A Commentary on Clinical Mechanisms. Psychoactives 2:2, pages 162-173.
Crossref
Yvan Beaussant & Kabir Nigam. (2023) Expending Perspectives on the Potential for Psychedelic-Assisted Therapies to Improve the Experience of Aging. The American Journal of Geriatric Psychiatry 31:1, pages 54-57.
Crossref
Torsten Passie, Jeffrey Guss & Rainer Krähenmann. (2022) Lower-dose psycholytic therapy – A neglected approach. Frontiers in Psychiatry 13.
Crossref
Kaitlin R. McManus, Regan Patrick, Meg I. Striepe, Mia J. Drury, Rosain Ozonsi, Brent P. Forester & Marc S. Weinberg. (2022) Psychedelics for Alzheimer's Disease Palliative Care. Advances in Psychiatry and Behavioral Health 2:1, pages 37-46.
Crossref
Don Wei, Sherab Tsheringla, James C. McPartland & A. Z. A. Stephen Azariah Allsop. (2022) Combinatorial approaches for treating neuropsychiatric social impairment. Philosophical Transactions of the Royal Society B: Biological Sciences 377:1858.
Crossref
Geoff J. Bathje, Eric Majeski & Mesphina Kudowor. (2022) Psychedelic integration: An analysis of the concept and its practice. Frontiers in Psychology 13.
Crossref
Alexandre Augusto de Deus Pontual, Luís Fernando Tófoli, Clarissa Mendonça Corradi-Webster, Kim van Oorsouw, Alicia Raquel Osuna Delgado & Johannes G. Ramaekers. (2022) The influence of ceremonial settings on mystical and challenging experiences occasioned by ayahuasca: A survey among ritualistic and religious ayahuasca users. Frontiers in Psychology 13.
Crossref
Seetal Dodd, Trevor R. Norman, Harris A. Eyre, Stephen M. Stahl, Arnie Phillips, André F. Carvalho & Michael Berk. (2022) Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. CNS Spectrums, pages 1-11.
Crossref
Maggie Kamila Kiraga, Kim P. C. Kuypers, Malin Vedoy Uthaug, Johannes G. Ramaekers & Natasha Leigh Mason. (2022) Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees. Frontiers in Psychiatry 13.
Crossref
Konstantin A. Demin, Olga V. Kupriyanova, Vadim A. Shevyrin, Ksenia A. Derzhavina, Nataliya A. Krotova, Nikita P. Ilyin, Tatiana O. Kolesnikova, David S. Galstyan, Yurii M. Kositsyn, Abubakar-Askhab S. Khaybaev, Maria V. Seredinskaya, Yaroslav Dubrovskii, Raziya G. Sadykova, Maria O. Nerush, Mikael S. Mor, Elena V. Petersen, Tatyana Strekalova, Evgeniya V. Efimova, Savelii R. Kuvarzin, Konstantin B. Yenkoyan, Dmitrii V. Bozhko, Vladislav O. Myrov, Sofia M. Kolchanova, Aleksander I. Polovian, Georgii K. Galumov & Allan V. Kalueff. (2022) Acute behavioral and Neurochemical Effects of Novel N -Benzyl-2-Phenylethylamine Derivatives in Adult Zebrafish . ACS Chemical Neuroscience 13:13, pages 1902-1922.
Crossref
Olga V. Kupriyanova, Vadim A. Shevyrin & Yuri M. Shafran. (2022) Potential of chromatography and mass spectrometry for the differentiation of three series of positional isomers of 2‐(dimethoxyphenyl)‐ N ‐(2‐halogenobenzyl)ethanamines . Drug Testing and Analysis 14:6, pages 1102-1115.
Crossref
Tomas Frymann, Sophie Whitney, David B. Yaden & Joshua Lipson. (2022) The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences. Frontiers in Psychology 13.
Crossref
Wayne Hall. (2021) Why was early therapeutic research on psychedelic drugs abandoned?. Psychological Medicine 52:1, pages 26-31.
Crossref
Dan J. Stein. 2022. Comprehensive Clinical Psychology. Comprehensive Clinical Psychology 97 104 .
Maxemiliano V. Vargas, Retsina Meyer, Arabo A. Avanes, Mark Rus & David E. Olson. (2021) Psychedelics and Other Psychoplastogens for Treating Mental Illness. Frontiers in Psychiatry 12.
Crossref
Sherry-Anne Muscat, Geralyn Dorothy Wright, Kristy Bergeron, Kevin W. Morin, Courtenay Richards Crouch & Glenn Hartelius. (2021) Ketamine-Assisted and Culturally Attuned Trauma Informed Psychotherapy as Adjunct to Traditional Indigenous Healing: Effecting Cultural Collaboration in Canadian Mental Health Care. Behavioral Sciences 11:9, pages 118.
Crossref
Gerhard Gründer & Henrik Jungaberle. (2021) The Potential Role of Psychedelic Drugs in Mental Health Care of the Future. Pharmacopsychiatry 54:04, pages 191-199.
Crossref
Brian S. Barnett & George R. Greer. (2021) Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer. Journal of the Academy of Consultation-Liaison Psychiatry 62:4, pages 460-471.
Crossref
M. V. Uthaug, N. L. Mason, S. W. Toennes, J. T. Reckweg, E. B. de Sousa Fernandes Perna, K. P. C. Kuypers, K. van Oorsouw, J. Riba & J. G. Ramaekers. (2021) A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharmacology 238:7, pages 1899-1910.
Crossref
Leor Roseman, Yiftach Ron, Antwan Saca, Natalie Ginsberg, Lisa Luan, Nadeem Karkabi, Rick Doblin & Robin Carhart-Harris. (2021) Relational Processes in Ayahuasca Groups of Palestinians and Israelis. Frontiers in Pharmacology 12.
Crossref
Bruno Romeo, Marianne Hermand, Amélie Pétillion, Laurent Karila & Amine Benyamina. (2021) Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. Journal of Psychiatric Research 137, pages 273-282.
Crossref
H. Kettner, F. E. Rosas, C. Timmermann, L. Kärtner, R. L. Carhart-Harris & L. Roseman. (2021) Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness. Frontiers in Pharmacology 12.
Crossref
Brandon Weiss, Joshua D. Miller, Nathan T. Carter & W. Keith Campbell. (2021) Examining changes in personality following shamanic ceremonial use of ayahuasca. Scientific Reports 11:1.
Crossref
Peter Gasser. 2022. Disruptive Psychopharmacology. Disruptive Psychopharmacology 23 34 .
Janis Phelps & James Henry. 2022. Disruptive Psychopharmacology. Disruptive Psychopharmacology 93 109 .
Bruno Romeo, Laurent Karila, Catherine Martelli & Amine Benyamina. (2020) Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis. Journal of Psychopharmacology 34:10, pages 1079-1085.
Crossref
Brian T Anderson, Alicia Danforth, Prof Robert Daroff, Christopher Stauffer, Eve Ekman, Gabrielle Agin-Liebes, Alexander Trope, Matthew Tyler Boden, Prof James Dilley, Jennifer Mitchell & Joshua Woolley. (2020) Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine 27, pages 100538.
Crossref
Dominique Denis-Lalonde & Andrew Estefan. (2020) Emerging Psychedelic-Assisted Therapies: Implications for Nursing Practice. Journal of Mental Health and Addiction Nursing 4:1, pages e1-e13.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.